IRulya Therapeutics Inc.
New Haven, Connecticut, United States · Biotechnology, Healthcare, Health Care
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other neurological diseases.
Key facts
- Headquarters
- New Haven, Connecticut, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (IRLA)
- Website
- cortexyme.com
Recent activity at IRulya Therapeutics Inc.
- : SEC 8-K (7.01): On October 19, 2026, IRulya Therapeutics Inc. made a Regulation FD Disclosure by posting its Corporate Presentation for October 2026 on their website. This presentation is available in the Investors section of the Company's site. The document may provide important updates or information relevant to investors regarding the company’s strategies and outlook. A copy of the Corporate Presentation is furnished as Exhibit 99.1 in the filing, indicating a commitment to transparency with stakeholders.
- : SEC 8-K (5.02): On October 8, 2026, Quince Therapeutics, Inc. announced the resignation of Dirk Thye, M.D., as Chief Executive Officer and Chief Medical Officer, along with his position as director. Simultaneously, Brendan Hannah stepped down as Chief Operating Officer, Chief Business Officer, and Chief Compliance Officer. The Board appointed Brigette Roberts, M.D., as the new Chief Executive Officer effective October 8, 2026. Dr. Roberts previously served as the Chief Corporate Affairs Officer and possesses significant experience, having raised over $45 million for Orphai Therapeutics, Inc. and led several key initiatives in her former roles. Under her employment agreement, Dr. Roberts will receive an annual salary of $600,000 with a target bonus of 50% of her salary.
- : SEC 8-K (5.02): On October 6, 2026, Quince Therapeutics, Inc. held a special meeting of stockholders where two significant plans were approved: the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan. The 2026 Plan allows for an initial reserve of 821,872 shares, with an automatic annual increase starting in 2027, whereas the 2026 ESPP starts with a reserve of 142,045 shares, which will also increase annually. These plans aim to incentivize employee performance and align their interests with those of shareholders. The board had previously approved these plans on July 29 and 30, 2026, pending stockholder approval, reflecting strategic intent to bolster workforce engagement and retention.
- : SEC 8-K (5.02): On September 30, 2026, three directors of Quince Therapeutics, Inc., namely June Bray, David Lamond, and Christopher Senner, tendered their conditional resignations from the Board of Directors. These resignations are set to take effect two business days after the Company’s Special Meeting of Stockholders, scheduled for October 6, 2026. Their resignations are contingent upon the shareholders approving three specific proposals to be presented during this meeting. This event signifies a potential shift in the Company's governance structure, contingent on the outcomes of the upcoming shareholder vote.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02):
- : SEC 8-K (8.01):
- : SEC 8-K (5.02): On July 29, 2026, Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc., and Brendan Hannah, the Chief Operating Officer, Chief Business Officer, and Chief Compliance Officer of the Company, tendered conditional resignations from their positions, effective two business days after the anticipated Special Meeting of Stockholders on September 25, 2026. Their resignations are contingent upon stockholder approval of three key proposals at the meeting, including the conversion of Series C Preferred Stock and an increase in the number of authorized shares from 250 million to 275 million. These changes are related to the Company's recent acquisition of Orphai Holdings Therapeutics, Inc. and associated financing transactions, indicating significant strategic developments for the Company.
- : Quince Therapeutics
- : SEC 8-K (8.01): On May 20, 2026, Quince Therapeutics, Inc. received notification from the Nasdaq Listing Qualifications Department confirming the Company has regained compliance with Nasdaq's continued listing requirements following a previous notice from March 17, 2026, regarding its market value. The recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, showed stockholders' equity of $15,672,000, satisfying the listing criteria. This matter is now closed, indicating strategic stability for the Company in maintaining its Nasdaq listing status.
IRulya Therapeutics Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Venture | $114.7M |
| May 2018 | Venture | $84.5M |
| Feb 2017 | Venture | $7.6M |
| Jan 2016 | Venture | $7.9M |
Leadership
- Roger Quy, Director
- Ilan Zipkin, Director
- Margi McLoughlin, Director
- David Lamond, Director
- Stephen Dominy, Director
- Casey Lynch, Executive Officer, Director
Verified email and direct lines for IRulya Therapeutics Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
IRulya Therapeutics Inc. in the news
Companies similar to IRulya Therapeutics Inc.
- Oruka Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Beam Therapeutics Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Immuneering · Biotechnology, Healthcare, Health Care, Therapeutics
- Olema Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Savara Inc · Biotechnology, Healthcare, Health Care, Therapeutics
About IRulya Therapeutics Inc.: questions and answers
What does IRulya Therapeutics Inc. do?
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other neurological diseases.
Where is IRulya Therapeutics Inc. headquartered?
IRulya Therapeutics Inc. is headquartered in New Haven, Connecticut, United States.
Has IRulya Therapeutics Inc. raised funding?
Yes. Fundz has recorded 4 funding events for IRulya Therapeutics Inc.. The most recent, $114.7M, was in Jun 2026.
What is the latest news on IRulya Therapeutics Inc.?
On Oct 19, 2026, SEC 8-K (7.01): On October 19, 2026, IRulya Therapeutics Inc. made a Regulation FD Disclosure by posting its Corporate Presentation for October 2026 on their website. This presentation is available in the Investors section of the Company's site. The document may provide important updates or informat
Is IRulya Therapeutics Inc. a public company?
Yes. IRulya Therapeutics Inc. is publicly traded under the ticker IRLA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy